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Objective: Neuropeptide Y affects several physiological functions, notably appetite 
regulation. We analysed the association between four single nucleotide polymorphisms 
(SNP) in the NPY gene (rs5574, rs16147, rs16139, rs17149106) and measures of obesity, 
dietary intake, physical activity, blood pressure, glucose and lipid metabolism from 
adolescence to young adulthood. 
Methods: The sample included both birth cohorts of the Estonian Children Personality 
Behaviour and Health Study at ages 15 (n = 1075 with available complete data), 18 (n = 913) 
and 25 (n = 926) years. Linear mixed-effects regression models were used for longitudinal 
association between NPY SNP-s and variables of interest. Associations at ages 15, 18 and 25 
were analysed by ANOVA.  
Results: Rs5574 CC-homozygotes had a greater increase per year in waist-to-hip ratio (WHR) 
and a smaller decrease in daily energy intake and carbohydrate intake from age 15 to 25 
years; fasting glucose and cholesterol were higher in rs5574 CC-homozygotes. Rs16147 TT-
homozygotes had higher body weight and a greater increase in sum of 5 skinfolds, waist 
circumference, WHR and waist-to-height ratio; however, they had lower carbohydrate intake 
throughout the observation period. Rs16147 TT-homozygotes and both rs16139 and 
rs17149106 heterozygotes had higher triglyceride levels. All NPY SNP-s were associated with 
blood pressure: rs5574 TT-and rs16147 CC-homozygotes had a smaller increase in diastolic 
blood pressure, while rs16139 and rs17149106 heterozygous had lower blood pressure 
throughout the study.   
Conclusion: Variants of the NPY gene were associated with measures of obesity, dietary 






















Obesity develops, when energy intake exceeds its expenditure. It was estimated that in 
year 2015 the prevalence of obesity was 5% among children and 12% in adults [1]. Variables 
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such as genetics, biology of development, psychological factors, diet and exercise, and the 
environment contribute to the development of obesity [2].  
Neuropeptide Y (NPY), a 36-amino acid neuropeptide encoded by the NPY gene, was 
first described by Tatemoto et al. (1982) almost 40 years ago [3]. NPY is widely expressed in 
the human CNS with the highest concentration found in the hypothalamic arcuate nucleus 
[4,5] as well as in the peripheral nervous system, the adrenal medulla, endothelium, immune 
cells, gut [6] and adipose tissue [7].  
After its discovery, several groups demonstrated that in animal models, central 
administration of NPY markedly increased food intake [8,9] leading to an increase in fat mass 
and body weight [8,10,11]. Transgenic mice overexpressing NPY under the dopamine‐beta‐
hydroxylase promoter (OE ‐NPY DBH) had increased adiposity, accompanied by impaired 
glucose tolerance and insulin resistance [12]. Moreover, in OE ‐NPY DBH mice, decreased fatty 
acid oxidation, accelerated cholesterol synthesis, hypercholesterolemia and hepatosteatosis 
were observed [13]. In humans, Sitticharoon et al. (2013) described a higher NPY mRNA 
expression in both subcutaneous and visceral adipose tissue in obese women compared to 
normal weight subjects; greater serum NPY levels were also observed [14]. NPY has a role in 
numerous other physiological functions including immune homeostasis [15], mood disorders 
[16], vasomotion, angiogenesis and cardiac remodeling [17]. NPY exerts its multiple effects 
through binding and activating its different receptor types: Y1, Y2, Y4, Y5, and Y6 [18].  Both 
Y1 and Y5 receptors in the paraventricular nucleus of the hypothalamus are involved in the 
regulation of food intake [19], Y1 receptors are related to immune function regulation [15] 
and Y1, Y2 and Y5 are the main cardiovascular homeostasis regulators [17]. 
Most common type of genetic variation are single nucleotide polymorphisms (SNP). 
Genome wide association studies have identified SNP-s in several genes, that have an effect 
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on body mass index (BMI) [20] and blood pressure [21] through different pathways [22]. It 
was demonstrated that a NPY SNP rs16147, located in the promoter region of the gene, 
altered NPY expression in vitro and accounted for more than half of the variation in 
expression in vivo [23]. Rs16147 C-allele was associated with decreased expression of mRNA 
in post-mortem brain and lymphoblasts [23], and lower levels of plasma NPY [23,24]. Other 
functional NPY gene variants have been described: Kallio et al. (2001) was the first to report 
the functional consequences of the rs16139 (T>C) substitution, demonstrating a higher 
overall plasma NPY concentration and faster heart rate [25]. Mitchell et al. (2008) replicated 
the results, showing that SNP rs16139 (T>C) in the NPY gene led to an increase in the levels 
of prohormone and elevated NPY secretion [26]. 
The effect of these variations in the NPY gene on human obesity and glucose and lipid 
metabolism has however been inconclusive. Zain et al. (2015) demonstrated that rs16147 
TT-homozygotes had higher odds (OR 1.27; 95% CI 1.04, 1.55) for obesity, compared to CC-
homozygotes [27], but Yeung et al. (2011) did not observe any association between rs16147 
and obesity among 2071 women from the Nurses’ Health Study (NHS) and 1268 men from 
the Health Professionals Follow-Up Study (HPFS) [28]. 
A few other NPY variants have been associated with obesity. NPY rs5574 TT-
homozygotes had lower odds (OR 0.76; 95% CI 0.61, 0.96) for obesity, compared to CC-
homozygotes [27]. Nevertheless, this was not observed in another study [28]. On the other 
hand, this investigation reported that NPY rs17149106 heterozygotes had higher odds (OR 
1.72; 95% CI 1.20, 2.47) for obesity, compared with GG-homozygotes, and carriers of the 
rs16139 C-allele had higher odds (OR 1.79; 95% CI 1.24, 2.60) for obesity, compared to TT-
homozygotes [28]. Findings were similar when comparing the mean difference in body mass 
index (BMI) by NPY genotype over the follow-up period (years 1986–2006) [28]. Rs16139 
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(T>C) was associated with higher BMI values in both men [29] and women [29,30], while 
cholesterol, triglycerides and blood pressure did not differ between genotype groups [30]. 
Another study by Karvonen et al. (2006) did not find an association between rs16139 and 
body weight in children, but observed an association with triglyceride levels [31].  
We have addressed the potential association of NPY variants with body composition in 
young age, paying special attention to factors leading to overweight such as diet and 
physical activity. The association between four SNP-s of the NPY gene rs16139, rs5574, 
rs16147 and rs17149106 of which two pairs of SNP-s (rs16147 with rs5574 and rs17149106 
with rs16139) are in strong linkage disequilibrium (r2 = 0.93 and 0.90, respectively; D′ = 0.96 
and 0.94, respectively) [28] and measures of obesity, dietary intake, physical activity, blood 
pressure and glucose and lipid metabolism was analysed in a longitudinal birth cohort study 
from 15 to 25 years of age. 
 
2. MATERIAL AND METHODS 
2.1 Study Sample 
The study sample was originally formed for the European Youth Heart Study (EYHS) 
(1998/1999) and later incorporated into the Estonian Children Personality Behaviour and 
Health Study (ECPBHS). The rationale and procedure for the original sample formation has 
been described in detail elsewhere [32]. In brief, ECPBHS is a longitudinal cohort study with a 
population representative sample of participants, all of European descent, with school as the 
sampling unit (original n=1238). All schools of Tartu County, Estonia, that agreed to 
participate (54 of the total of 56) were included into the sampling and 25 schools were 
selected. All children from grades 3 (younger birth cohort, aged 9 years) and grades 9 (older 
birth cohort, aged 15 years) were invited to participate [33]. Follow-up studies for the 
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younger birth cohort took place in year 2004 at age 15 years (n = 483), in year 2007 at age 18 
years (n = 454) and in year 2014 at age 25 years (n = 441) and for the older birth cohort in 
year 2001 at age 18 years (n = 417 + additional 62) and in year 2008 at 25 years (n = 541). 
The sample of this analysis comprises of non-pregnant individuals with available data on 
anthropometric measurements, blood pressure, metabolic biomarkers, physical activity, 
dietary intake and rs16139, rs5574, rs16147 and rs17149106 genotype at ages 15, 18 and 25 
years. For the analysis, data from both birth cohorts of the ECPBHS was merged, with 
available complete data as follows: age 15 (n = 1075), 18 (n = 913) and 25 (n = 926). 
Before participation, written informed consent was obtained from the subjects and, in 
case of subjects aged < 18 years, also from their parents. The study was approved by the 
Ethics Review Committee on Human Research of the University of Tartu and conducted in 
accordance with the Declaration of Helsinki. 
 
2.2 Anthropometric measurements, blood pressure and metabolic biomarkers 
Height and weight were measured using standardized procedures and body mass 
index (BMI) was calculated as weight / height squared (kg/m2). Skinfold thickness was taken 
at the biceps, triceps, subscapular, suprailiac and medial calf areas on the left side of the 
body using a Harpenden caliper (Baty, West Sussex, England). Waist circumference (WC) was 
measured between the lower rib margin and the iliac crest, at the end of gentle expiration 
and hip circumference (HC) at the widest part of the gluteal region. Waist-to-hip ratio (WHR) 
and waist-to-height ratio (WHtR) were calculated as waist circumference / hip circumference 
(units) and waist circumference / height (units), respectively. All anthropometrical 
measurements were taken twice and a mean value was used.  
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Resting systolic and diastolic blood pressure (BP) was obtained from the left arm with 
an automatic oscillometric method in a sitting position. A mean value of five consecutive 
measurements at 2 min intervals was used. 
Venous blood samples were taken from the antecubital vein after an 8–12 h fast and 
analysed in a certified clinical laboratory. 
 
2.3 Dietary intake 
During the day(s) before the study day, the subjects were asked to complete a 24h 
(year 1998), 48h (years 2001, 2004, 2007) or 72h (years 2008, 2014) diet record at home. On 
the study day portion sizes, that were not recorded in the food diary, were elaborated using 
pictures of portion sizes [34] during a face-to-face interview. The procedure for the 
assessment of dietary intake has been described in detail elsewhere [35].  
 
2.4 Cardiorespiratory fitness (CRF) and physical activity 
CRF was determined by a cycle-ergometer test and defined as maximum power output 
(MPO) per kilogram of body weight (MPO/kg). The protocol for aerobic fitness originates 
from the European Youth Heart Study [36] and the procedure has been described in detail 
elsewhere [37].  
Physical activity was assessed using self- and parent-reported questionnaires. 
Individual physical activity scores were calculated and standardized physical activity scores 
(z-scores) were used. The formation of physical activity score has been described in detail 
elsewhere [37].  
 
2.5 Genotyping of NPY rs5574, rs16147, rs16139 and rs17149106 
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Genomic DNA was extracted from venous blood samples using Qiagen QIAamp® DNA Blood 
Midi Kit. The real-time polymerase chain reaction (RT-PCR) for genotyping the NPY rs5574, 
rs16147, rs16139 and rs17149106 polymorphisms was performed using a TaqMan Pre-
Designed SNP Genotyping Assay (Applied Biosystems; Foster City, CA, USA) containing 
primers and fluorescent probes. Context sequence [VIC/FAM] for rs5574 was as follows: 
TTTTTTCCAGATATGGAAAACGATC[C/T]AGCCCAGAGACACTGATTTCAGACC; for rs16147: 
GCTTCCTACTCCGGCACCCAGTGGG[C/T]TGGTAGTCCTGTTGGCAGGAGACAA; for rs16139: 
CTGCAGATGCTAGGTAACAAGCGAC[C/T]GGGGCTGTCCGGACTGACCCTCGCC; for rs17149106: 
CCCCTGAAACCACGGGCGGGGGTGG[G/T]GTGGGGAGCGCAGCTTTGGGACCCT. Genotyping 
reactions were performed in a total volume of 10 µl with ~25 ng of template DNA. RT-PCR 
reaction components and final concentrations were as follows: 1:5 5 x HOT FIREPol® Probe 
qPCR Mix Plus (ROX) (Solis BioDyne) and 1:20 80 x TaqMan Primers Probe. Reactions were 
performed on the Applied Biosystems ViiA™ 7 Real-Time PCR System. The amplification 
procedure consisted of an initial denaturation step at 95 °C for 12 min and 40 cycles of 95 °C 
for 15 s and 60 °C for 1 min. Positive and negative controls were added to each reaction 
plate. No inconsistencies occurred. Genotyping was performed blind to all phenotypic data. 
Allele frequencies agreed with National Center for Biotechnology Information database and 
published reports.  
 
2.6 Statistical analysis 
Statistical analysis was performed using Stata 14 software (StataCorp LP, College 
Station, Texas, USA). Level of significance was set at 0.05.  
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Linear mixed-effects regression models with random intercept and random slope were 
used to assess the association between NPY rs5574, rs16147, rs16139, rs17149106 and 
measures of obesity, dietary intake, BP, glucose and lipid metabolism, CRF and physical 
activity. Mixed modelling procedure considers the correlations between repeated 
measurements within each subject and allows the inclusion of subjects with different 
number of observations, assuming that the missingness is random [38]. Measures of obesity, 
dietary intake, BP, glucose- and lipid metabolism, CRF and physical activity at baseline (age 
15 years) and at follow up points (18 years and 25 years) were inserted as dependent 
variables and NPY rs5574, rs16147, rs16139 and rs17149106 genotypes as the independent 
variables. Time was treated as continuous.  
Exchangeable or unstructured covariance structure and restricted maximum likelihood 
method was used. Likelihood-ratio test was used to assess the goodness of fit of the 
statistical models. Interaction with time was not included in the final model if interaction 
with time lacked significance and the likelihood-ratio test did not show superiority of the 
more complicated model. Models were not adjusted for physical activity, because the 
association between NPY SNPs and physical activity was not significant.  
 
3. RESULTS 
3.1 NPY rs5574, rs16147, rs16139 and rs17149106 genotype distribution  
Genotype data for NPY rs5574, rs16147, rs16139 and rs17149106 were available at 
different ages as follows: 15 years n = 1075 (44.7% male), 18 years n = 913 (43.7% male), and 
25 years n = 926 (45.1% male). The distribution of TT, CT and CC genotypes of the rs5574 in 
the studied sample at age 15 years was 19.9%, 51.1%, 29.0% and of the rs16147 was 24.1%, 
51.4% and 24.5%, respectively. The distribution of the rs16139 CC, CT and TT genotypes at 
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age 15 years was 0.6%, 12.5%, 86.8% and rs17149106 GG, GT, TT 86.6%, 12.8% and 0.6%, 
respectively. Distribution of men and women did not differ between genotype groups 
(Supplementary Table 1). Rare homozygotes of the rs16139 and rs17149106 were not 
included in the statistical analysis, because of the very low prevalence and highly variable 
results that on average substantially differed from heterozygotes. Genotype frequencies 
were in Hardy–Weinberg equilibrium. 
 
3.2 Measures of obesity and abdominal obesity 
In linear mixed-effects regression models with time × rs5574 interaction a smaller 
increase (p = 0.015 for interaction) per year in WHR was observed in TT-homozygotes 
compared to CC-homozygotes from 15 to 25 years of age (Tables 1 and 3). 
During the study period, rs16147 CC-homozygotes compared to TT-homozygotes had a 
significantly (p = 0.013) lower body weight (Table 1). In the study sample, the mean change 
in body weight was 1.30 kg (95% CI 1.23, 1.37) per year.  
A smaller (p < 0.05 for interaction) increase in sum of 5 skinfolds, WHR and WHtR per 
year was observed in heterozygotes and CC-homozygotes, compared to TT-homozygotes in 
models with time × rs16147 interaction. Heterozygotes compared to TT-homozygotes had a 
smaller (p = 0.034 for interaction) increase per year in WC (Tables 1 and 3).  
No longitudinal association between measures of obesity or abdominal obesity and 
rs16139 or rs17149106 was observed (Table 2). 
A one-way ANOVA test at ages 15, 18 and 25 years revealed several associations 
between weight, BMI, WC, WHR and rs16147 genotype. Rs16147 CC-homozygotes had 
significantly lower body weight at age 15 years (by –2.45 kg; 95% CI –0.27, 4.63; p = 0.021), 
18 years (by –2.97 kg; 95% CI –0.17, –5.78; p = 0.033) and 25 years (by –4.00 kg; 95% CI –
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0.47, –7.54; p = 0.020), compared to TT-homozygotes. At age 25 years CC-homozygotes had 
significantly lower BMI (by –0.95 kg/m2; 95% CI –0.01, –1.89; p = 0.046) and WC (by – 2.92 
cm; 95% CI –0.36, –5.49; p = 0.019) and both heterozygotes and CC homozygotes had 
smaller WHR (by –0.01 units; 95% CI –0.001, –0.03; p = 0.033 and by –0.02 units; 95% CI –
0.001, –0.003; p = 0.027) compared to TT-homozygotes, respectively (Supplementary Table 
3).  
An association between obesity, abdominal obesity and rs5574, rs16139 or 
rs17149106 was not observed by one-way ANOVA at ages 15 years, 18 years and 25 years 
(Supplementary Tables 2 and 4–5). 
 
3.3 Blood pressure 
In models with time × rs5574 and time × rs16147 interaction a smaller (p < 0.05 for 
interaction) increase per year in diastolic blood pressure was observed in TT-homozygotes 
compared to CC-homozygotes and CC-homozygotes, compared to TT-homozygotes, 
respectively (Tables 1 and 3). 
Both rs16139 and rs17149106 heterozygotes had significantly (p < 0.05) lower systolic- 
and diastolic blood pressure from 15 to 25 years of age compared to TT-homozygotes and 
GG-homozygotes, respectively (Table 2). In the analysed sample, the mean change per year 
was 0.49 mmHg (95% CI 0.40, 0.57) in systolic blood pressure and 0.43 mmHg (95% CI 0.38, 
0.49) in diastolic blood pressure. 
Rs16139 heterozygotes had significantly lower diastolic blood pressure at age 18 years 
(by –2.41 mmHg; 95% CI –3.91, 0.91; p = 0.002), according to one-way ANOVA 




3.4 Metabolic biomarkers 
According to the models, rs5574 heterozygotes compared to CC-homozygotes had 
significantly (p = 0.011) lower levels of fasting blood glucose and both rs16147 heterozygotes 
and CC-homozygotes had lower (p < 0.05) fasting blood glucose compared to TT-
homozygotes, from age 15 to 25 years (Table 1).  
Interestingly, cholesterol and HDL-cholesterol levels were higher (p < 0.05) in rs5574 
heterozygotes compared to CC-homozygotes and in rs16147 heterozygotes, compared to TT-
homozygotes from 15 to 25 years of age (Table 1).  
Rs17149106 heterozygotes had higher (p = 0.033) cholesterol levels, compared to GG-
homozygotes from age 15 to 25 years of age (Table 2). Models with time × rs16139 and time 
× rs17149106 interaction demonstrated a greater (p < 0.05 for interaction) increase per year 
in heterozygotes in triglyceride levels (Tables 2–3). 
Mean change in fasting blood glucose was –0.005 mmol/L (95% CI –0.001, 0.009), 
cholesterol was 0.04 mmol/L (95% CI 0.04, 0.05) and HDL-cholesterol was 0.007 mmol/l 
(95% CI 0.005, 0.009) per year, in the analysed sample.  
According to one-way ANOVA rs5574 heterozygotes had higher (0.016 mmol/l; 95% CI 
0.003, 0.309; p = 0.045) cholesterol levels compared to CC-homozygotes and rs16139 
heterozygotes had higher cholesterol (by 0.23 mmol/l; 95% CI 0.07, 0.40; p = 0.006) and LDL-
cholesterol (by 0.16 mmol/l; 0.02, 0.30; p = 0.021) levels, compared to TT-homozygotes at 
age 18 years. Higher cholesterol (by 0.25 mmol/; 95% CI 0.09, 0.42; p = 0.003) and LDL-
cholesterol (by 0.19 mmol/l, 95% CI 0.05, 0.32; p = 0.007) levels, at age 18 years, were also 
observed in rs17149106 heterozygotes compared to GG-homozygotes (Supplementary 




3.5 Dietary intake 
Linear mixed-effects regression models with time × rs5574 interaction demonstrated a 
significant (p < 0.05) difference in the rate of change per year in daily energy intake and 
carbohydrate intake between CC-homozygotes and TT-homozygotes, the latter having a 
larger decrease per year (Tables 1 and 3).  
From age 15 to 25 years, rs5574 heterozygotes had significantly (p < 0.002) lower 
protein intake (E%), compared to CC-homozygotes (Table 1).  
Surprisingly, CC-homozygotes of the rs16147 had greater (p = 0.029) carbohydrate 
intake from 15 to 25 years of age, compared to TT-homozygotes. During the study period 
both rs16147 heterozygotes and CC-homozygotes had greater (p < 0.05) carbohydrate intake 
(E%), compared to TT-homozygotes. Lower protein (E%) intake was observed in 
heterozygotes, compared to TT-homozygotes (Table 1). 
Rs16139 and rs17149106 heterozygotes had significantly (p < 0.05) lower protein 
intake compared to TT-homozygotes and GG-homozygotes from 15 to 25 years of age, 
respectively (Table 2). In models with time × rs16139 and time × rs17149106 interaction a 
smaller increase in the rate of change per year in protein (E%) intake was observed in 
heterozygotes compared to TT-homozygotes and GG-homozygotes, respectively (Tables 2–
3). 
In the study sample, the mean change per year in carbohydrate intake (g) was –8.73 g 
(95% CI –9.70, –7.77), protein (g) intake was 0.88 g (95% CI 0.63, 1.14), protein (E%) intake 
was 0.30 E% (95% CI 0.27, 0.34), and carbohydrate (E%) intake was –0.55 E% (95% CI 0.48, 
0.62). 
At age 15 years, rs5574 CC-homozygotes had lower daily energy intake (by –196.29 
kcal/day; 95% CI –2.47, –390.10; p = 0.046) and carbohydrate intake (by –0.59 g/kg; 95% CI –
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0.14, –1.05; p = 0.006), compared to TT-homozygotes, according to one-way ANOVA. 
Heterozygotes, compared to CC-homozygotes, had significantly lower protein intake (E%) (by 
0.68 E%; 95% CI 0.12, 1.24; p = 0.011) at age 18 years (Supplementary Table 2).  
Rs16147 heterozygotes had significantly lower protein intake (E%) (by –0.78 E%; –0.18, 
–1.37; p = 0.005), compared to TT-homozygotes and both heterozygotes (by 2.03 E%; 0.33, 
3.72; p = 0.013) and CC-homozygotes (by 2.00 E%; 0.06, 3.94; p = 0.041) had larger 
carbohydrate intake (E%), compared to TT-homozygotes at age 18 years (Supplementary 
Table 3). 
Rs16139 heterozygotes had lower (p < 0.05) protein intake (g), compared to TT-
homozygotes at age 15 years (by –5.91 g; 95% CI –11.74, –0.09; p = 0.047) and 25 years (by – 
6.74 g; 95% CI – 13.33, – 0.15; p = 0.045) (Supplementary Table 4) and at age 25 years 
rs17149106 heterozygotes had lower protein intake (by –7.09 g; 95% CI –13.68, –0.50; p = 
0.035 and by –1.03 E%; 95% CI –1.82, –0.23; p = 0.011) compared to GG-homozygotes 
(Supplementary Table 5).  
 
3.6 MPO and physical activity 
Linear mixed effects regression models did not identify statistically significant 
longitudinal associations between MPO, physical activity and rs5574, rs16147, rs16139 and 
rs17149106 genotypes.  
Rs16139 heterozygotes had lower MPO (by –0.17 per kg; –0.34, 0.02; p = 0.026) 





Studies describing the association between NPY genetic variants and weight gain or 
obesity have been inconclusive, some showing an association [27,29,30,39] while others 
demonstrating no effect [28,31]. However, studies analysing the association between 
variants of the NPY and obesity have differed regarding the age of the population under 
investigation, so this should be considered as a possible reason for variation. 
A case-cohort study by Zain et al. (2015) recruited 1113 apparently healthy children 
aged 13 years and demonstrated that the frequency of the rs16147 T-allele was significantly 
higher in overweight and obese children compared to controls (OR 1.27; 95% CI 1.04, 1.55; p 
= 0.022), whereas the prevalence of the rs5574 T-allele was significantly higher in the 
controls (OR 0.76; 95% CI 0.61, 0.96; p = 0.020) [27]. Indeed, it has been observed that the 
two pairs of SNPs, rs17149106 with rs16139 (r2 = 0.93, D′ = 0.96) and rs16147 with rs5574 (r2 
= 0.90, D′= 0.94), are in strong linkage disequilibrium [28], and this fits well with the results 
in this study. Similarly, Olza et al. (2013) observed an association between the rs16147 T-
allele and obesity (OR 1.38; 95% CI 1.08–1.78 for allelic effect) among Spanish children in a 
multicenter case-control study [39] that did not genotype rs5547.  
In contrast, Yeung et al. (2011) did not observe any association between rs16147 or 
rs5574 and obesity in middle aged men and women. Instead, they demonstrated an increase 
in the risk of obesity among rs17149106 heterozygotes compared to GG-homozygotes and 
rs16139 C-allele carriers compared to TT-homozygotes [28]. Similarly, Ding et al. (2005) 
observed that among normal weight adults, rs16139 C-allele (n = 1246) carriers had higher 
BMI, with no gender disparity [30] and van Rossum et al. (2006) showed that the risk of 
overweight was greater among rs16139 C-allele carriers (OR 3.3; 95% CI 1.2; 8.9) [29]. In 




We observed an association between rs5574 and measures of abdominal obesity, 
where CC-homozygotes had a greater increase per year in WHR from adolescence to young 
adulthood. Rs16147 TT-homozygotes had higher body weight throughout the study period 
and a greater increase in sum of five skinfolds, waist circumference, WHR and WHtR from 
age 15 to 25 years. No association between rs16139 or rs17149106 and body weight, BMI, 
waist and hip circumference or their ratio was observed at this age. Thus, our findings are 
consistent with literature with regards to the association of these NPY variants with obesity 
that have previously been positive at a young age, and the absence of association with those 
variants for which evidence was obtained in studies on middle-aged samples. 
Genome wide association studies, including subjects of very heterogenous age 
groups, have not reported any association between NPY gene variants and obesity 
[20,40,41]. However, Winkler et al. (2015) demonstrated in a genome wide study the age-
specificity of association of genetic variants contributing to BMI, as some had larger effects 
in younger (< 50 years) and other in older adults (≥ 50 years) [42]. This would be compatible 
with the effect of NPY rs5574 and rs16147 on measures of obesity being pronounced in 
childhood and young adulthood, while the effect of rs16139 and rs17149106 would develop 
later in adulthood. However, our sample is, for the time being, limited with the age 25 being 
the last point of observation. It should also be noted that the sample of ECPBHS consists of 
individuals of only European descent and therefore we cannot be sure if the associations are 
similar in other ethnicities. 
In terms of the mechanism of increased weight gain, we have observed that the 
rs5574 CC-homozygotes had a smaller decrease in daily energy intake (kcal/day) and 
carbohydrate intake (g) per year from age 15 to 25 years. Inversely, TT-homozygotes of the 
rs16147 had lower carbohydrate intake at every timepoint from childhood to young 
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adulthood despite of their higher indicators of fat content; however, the overall energy 
intake was not different between genotypes. Despite suggestive results in animal studies, 
our present study and others [28,31] have not been able to demonstrate a clear relationship 
with energy intake. Thus, while some of our results appear to suggest that the NPY-mediated 
obesity is simply related to daily energy intake and carbohydrate intake, others are not in 
line with this notion. Considering the extensive physiological and homeostatic role of NPY in 
the mammalian organism, it is probable that in addition to food intake NPY plays a role in 
the development of obesity through other pathways, such as lipolysis inhibition [43], which 
need further study.  
It has been proposed that NPY and its receptor system has a causal role in the 
development of type 2 diabetes and atherosclerotic cardiovascular disease [44]. Animal and 
in vitro studies have described an inhibition of glucose dependent insulin release by NPY 
treatment [45,46] and an increase in NPY mRNA expression in the arcuate nucleus in mice 
with gestational diabetes [47]. In humans, it has been demonstrated in middle aged and 
older subjects from Finnish and Dutch ancestry that regarding the rs16139 variation (T>C), 
the minor C-allele associated with higher NPY release was also associated with accelerated 
increase  of  the  common  carotid  artery intima-media thickness, greater systolic and 
diastolic blood pressure [48], higher serum cholesterol and LDL-cholesterol levels [49] and 
worse glycemic control, higher triglyceride levels and higher prevalence of coronary heart 
disease [50].  
Although we did not find any association between rs16139 and increased weight gain 
or higher WHR, we observed a greater increase per year in triglyceride levels in rs16139 
heterozygotes compared to TT-homozygotes and rs17149106 heterozygotes compared to 
GG-homozygotes. In addition, we found that rs5574 CC-homozygotes and rs16147 TT-
19 
 
homozygotes had higher fasting blood glucose levels. Then, our results regarding 
cholesterol, indicating higher levels in rs5574 heterozygotes compared to CC-homozygotes 
and rs16147 heterozygotes compared to TT-homozygotes remain hard to interpret, and 
should remain in waiting of whether they can be independently replicated. 
Previously, several SNP-s in genes that encode proteins in secretory pathways and 
have been associated with psychiatric and metabolic diseases have also been associated 
with blood pressure. For prominent examples, SNP-s in the CHGA [51] and CHGB [52,53] 
genes have been associated with schizophrenia. Reduced levels of chromogranin A and B in 
the cerebrospinal fluid in patients with schizophrenia, have been noted [54]. In addition, 
genetic variation in CHGA have also been associated with blood pressure [55,56]. For 
example, rs7610 was linked with hypertensive renal disease [57] and rs9658667 with 
hypertension [58,59]. Similarly, polymorphisms rs2821 [60] and rs236140 [61] in the CHGB 
gene were linked with high blood pressure and rs1017448 in the SCG2 gene was associated 
with blood pressure elevation [62]. We found associations between all the four NPY SNP-s 
and blood pressure. Rs5574 CC-homozygotes and rs16147 TT-homozygotes had a higher 
increase in diastolic blood pressure from 15 to 25 years of age. However, our results also 
demonstrated that contrary to the findings in middle aged and older adults [48,50], from 
adolescence to young adulthood the rs16139 heterozygotes and rs17149106 heterozygotes 
had lower systolic and diastolic blood pressure as compared to the TT and GG homozygotes.  
It has been demonstrated that both food restriction and physical activity induced 
negative energy balance led to an increase in hypothalamic NPY concentration [63], yet in 
rats with streptozotocin induced diabetes, low intensity physical activity had a suppressive 
effect on the hypothalamic NPY expression [64]. We did not identify any association 
between NPY SNP-s and physical activity. However, rs16139 heterozygotes compared to GG-
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Our results confirm some of previous findings and, together with literature, suggest 
that the effect of NPY variants on measures of obesity may be age-related and thus should 
be further studied longitudinally over a broad age range. It is likely that at least partially, 
food intake mediates the NPY-associated obesity. Nevertheless, because of conflicting 
results, other pathways should be explored. Our results support the association between 
NPY and glucose- and lipid metabolism. The association between NPY variants and blood 
pressure needs further study where age, as a modifying factor, is considered.  
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Table 1. Estimated main effects (mean and 95% CI) and estimated main and interaction effects (mean and 95% CI) in anthropometric measurements, dietary 
intake and physical activity of the ECPBHS sample from 15 to 25 years of age between NPY rs5574 and rs16147 genotype according to the linear mixed-
effects regression model. 
  rs5574    rs16147  
 Coefficient 95% CI p value  Coefficient 95% CI p value 
Body weight (kg) a    Body weight (kg) c    
CT genotype  –1.107 –2.518; 0.305 0.124 CT genotype  –1.318 –2.814; 0.179 0.084 
TT genotype  –1.610 –3.372; 0.151 0.073 CC genotype  –2.195 –3.931; –0.459 0.013 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
BMI (kg/m2) a    BMI (kg/m2) c    
CT genotype  –0.150 –0.541; 0.242 0.454 CT genotype  –0.204 –0.619; 0.212 0.337 
TT genotype  –0.402 –0.892; 0.087 0.107 CC genotype  –0.437 –0.920; 0.045 0.076 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Sum of 5 skinfolds (mm) a    Sum of 5 skinfolds (mm) d    
CT genotype  –0.033 –3.662; 3.595 0.986 CT genotype  8.821 –0.493; 18.135 0.063 
TT genotype  –1.567 –6.096; 2.961 0.498 CC genotype  9.297 –1.473; 20.068 0.091 
CT genotype × time    CT genotype × time –0.506 –1.010; –0.001 0.049 
TT genotype × time    CC genotype × time –0.614 –1.196; –0.033 0.038 
WC (cm) a    WC (cm) d    
CT genotype  –0.636 –1.539; 0.266 0.167 CT genotype  1.624 –0.682; 3.930 0.167 
TT genotype  –0.757 –1.884; 0.370 0.188 CC genotype  1.440 –1.220; 4.101 0.289 
CT genotype × time    CT genotype × time –0.152 –0.293; –0.011 0.034 
TT genotype × time    CC genotype × time –0.162 –0.324; 0 0.050 
HC (cm) a    HC (cm) c    
CT genotype  –0.146 –1.010; 0.718 0.740 CT genotype  –0.281 –1.197; 0.635 0.548 
TT genotype  –0.797 –1.874; 0.281 0.147 CC genotype  –1.045 –2.107; 0.018 0.054 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
 WHR (units) b    WHR (units) d    
CT genotype  0.0028 –0.0117; 0.0173 0.705 CT genotype  0.0086 –0.0068; 0.0241 0.272 
TT genotype  0.0164 –0.0016; 0.0344 0.074 CC genotype  0.0189 0.0011; 0.0367 0.038 
CT genotype × time –0.0006 –0.0014; 0.0002 0.129 CT genotype × time –0.0010 –0.0018; –0.0001 0.026 
TT genotype × time –0.0012 –0.0022; –0.0002 0.015 CC genotype × time –0.0014 –0.0024; –0.0004 0.004 
WHtR (units) a    WHtR (units) d    
CT genotype  –0.0016 –0.0064; 0.0032 0.514 CT genotype  0.0136 0.0003; 0.0268 0.044 
TT genotype  –0.0031 –0.0091; 0.0029 0.314 CC genotype  0.0126 –0.0027; 0.0278 0.107 
CT genotype × time    CT genotype × time 0.0010 –0.0018; –0.0002 0.016 
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TT genotype × time    CC genotype × time –0.0010 –0.0019; –0.0001 0.034 
Systolic BP (mmHg) a    Systolic BP (mmHg) c    
CT genotype  –0.831 –2.223; 0.561 0.242 CT genotype  –0.819 –2.295; 0.658 0.277 
TT genotype  0.144 –1.592; 1.880 0.871 CC genotype  0.201 –1.511; 1.912 0.818 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Diastolic BP (mmHg) b    Diastolic BP (mmHg) d    
CT genotype  1.193 –1.134; 3.728 0.356 CT genotype  1.350 –1.344; 4.044 0.326 
TT genotype  3.497 0.361; 6.634 0.029 CC genotype  3.115 0.007; 6.223 0.049 
CT genotype × time –0.056 –0.193; 0.081 0.425 CT genotype × time –0.071 –0.217; 0.074 0.336 
TT genotype × time –0.193 –0.362; –0.024 0.025 CC genotype × time –0.169 –0.336; –0.001 0.049 
Glucose (mmol/L) a    Glucose (mmol/L) c    
CT genotype  –0.066 –0.116; –0.015 0.011 CT genotype  –0.060 –0.113; –0.008 0.023 
TT genotype  –0.045 –0.107; 0.018 0.162 CC genotype  –0.071 –0.132; –0.011 0.021 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Insulin (mU/L) a    Insulin (mU/L) c    
CT genotype  –0.339 –0.892; 0.214 0.229 CT genotype  –0.509 –1.115; 0.097 0.100 
TT genotype  0.146 –0.540; 0.832 0.678 CC genotype  –0.048 –0.747; 0.651 0.892 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Cholesterol (mmol/L) a    Cholesterol (mmol/L) c    
CT genotype  0.102 0.009; 0.194 0.031 CT genotype  0.112 0.014; 0.211 0.025 
TT genotype  0.042 –0.073; 0.158 0.470 CC genotype  0.061 –0.052; 0.175 0.291 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
HDL-cholesterol (mmol/L) a    HDL-cholesterol (mmol/L) c    
CT genotype  0.041 0.001; 0.082 0.046 CT genotype  0.027 –0.016; 0.070 0.221 
TT genotype  0.028 –0.023; 0.078 0.282 CC genotype  0.028 –0.022; 0.078 0.272 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
LDL-cholesterol (mmol/L) a    LDL-cholesterol (mmol/L) c    
CT genotype  0.045 –0.042; 0.132 0.306 CT genotype  0.068 –0.024; 0.160 0.149 
TT genotype  –0.005 –0.113; 0.103 0.929 CC genotype  0.022 –0.085; 0.128 0.692 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Triglycerides (mmol/L) a    Triglycerides (mmol/L) c    
CT genotype  0.006 –0.044; 0.056 0.825 CT genotype  0.006 –0.047; 0.059 0.822 
TT genotype  –0.020 –0.082; 0.042 0.528 CC genotype  –0.002 –0.063; 0.060 0.954 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
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Energy intake (kcal) b1    Energy intake (kcal) c1    
CT genotype  121.522 –178.810; 421.854 0.428 CT genotype  77.581 –241.493; 396.654 0.634 
TT genotype  459.346 87.135; 831.557 0.016 CC genotype  355.584 –13.657; 724.825 0.059 
CT genotype × time –4.959 –18.945; 9.026 0.487 CT genotype × time –3.384 –18.235; 11.467 0.655 
TT genotype × time –17.687 –34.921; –0.452 0.044 CC genotype × time –14.721 –31.866; 2.423 0.092 
Protein (g) a1    Protein (g) c1    
CT genotype  –1.218 –4.499; 2.063 0.467 CT genotype  –1.932 –5.416; 1.552 0.277 
TT genotype  2.507 –1.565; 6.578 0.228 CC genotype  0.338 –3.695; 4.371 0.869 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Lipids (g) a1    Lipids (g) c1    
CT genotype  0.192 –3.764; 4.147 0.924 CT genotype  –0.915 –5.114; 3.285 0.669 
TT genotype  3.704 –1.187; 8.595 0.138 CC genotype  1.555 –3.298; 6.408 0.530 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Carbohydrates (g) b1    Carbohydrates (g) c1    
CT genotype  15.486 –23.180; 54.152 0.432 CT genotype  6.473 –4.314; 17.261 0.240 
TT genotype  64.996 17.285; 112.707 0.008 CC genotype  13.920 1.439; 26.402 0.029 
CT genotype × time –0.458 –2.468; 1.553 0.656 CT genotype × time    
TT genotype × time –2.536 –5.005; –0.067 0.044 CC genotype × time    
Protein E% a    Protein E% c    
CT genotype  –0.489 –0.793; –0.186 0.002 CT genotype  –0.542 –0.864; –0.220 0.001 
TT genotype  –0.203 –0.580; 0.173 0.290 CC genotype  –0.307 –0.679; 0.065 0.106 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Lipids E% a    Lipids E% c    
CT genotype  –0.280 –0.934; 0.374 0.401 CT genotype  –0.646 –1.337; 0.046 0.067 
TT genotype  –0.338 –1.147; 0.470 0.412 CC genotype  –0.707 –1.504; 0.091 0.082 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
Carbohydrates E% a    Carbohydrates E% c    
CT genotype  0.664 –0.113; –1.441 0.094 CT genotype  1.508 0.221; 1.895 0.013 
TT genotype  0.530 –0.432; 1.492 0.280 CC genotype  1.021 0.055; 1.987 0.038 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
MPO/kg a    MPO/kg c    
CT genotype  –0.058 –0.144; 0.028 0.183 CT genotype  –0.051 –0.143; 0.040 0.269 
TT genotype  0.036 –0.071; 0.143 0.510 CC genotype  0.009 –0.097; 0.114 0.873 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
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Standard. PA score a Standard. PA score c 
CT genotype  0.045 –0.051; 0.141 0.361 CT genotype  0.012 –0.090; 0.114 0.821 
TT genotype  0.030 –0.089; 0.149 0.617 CC genotype  0.007 –0.111; 0.124 0.912 
CT genotype × time    CT genotype × time    
TT genotype × time    CC genotype × time    
a Coefficient can be interpreted as the mean difference in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage 
from daily energy intake (E%) between rs5574 CT and CC genotype or between TT and CC genotype at each timepoint. 
b Difference in the rate of change in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage from daily energy intake 
(E%) between rs5574 CT and CC genotype or between TT and CC genotype can be calculated as the sum of main effect coefficient and time × interaction coefficient at given timepoint.  
c Coefficient can be interpreted as the mean difference in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage 
from daily energy intake (E%) between rs16147 CT and TT genotype or between CC and TT genotype at each timepoint. 
d Difference in the rate of change in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage from daily energy intake 
(E%) between rs16147 CT and TT genotype or between CC and TT genotype can be calculated as the sum of main effect coefficient and time × interaction coefficient at given timepoint.  
1 adjusted for body weight 

















Table 2. Estimated main effects (mean and 95% CI) and estimated main and interaction effects (mean and 95% CI) in anthropometric measurements, dietary 
intake and physical activity of the ECPBHS sample from 15 to 25 years of age between NPY rs16139 and NPY rs17149106 genotype according to the linear 
mixed-effects regression model. 
  rs16139    rs17149106  
 Coefficient 95% CI  P value  Coefficient 95% CI  P value 
Body weight (kg) e    Body weight (kg) g    
CT genotype –1.714 –3.538; 0.110 0.066 GT genotype –1.588 –3.402; 0.226 0.086 
CT genotype × time    GT genotype × time    
BMI (kg/m2) e    BMI (kg/m2) g    
CT genotype –0.183 –0.691; 0.324 0.479 GT genotype –0.098 –0.603; 0.407 0.704 
CT genotype × time    GT genotype × time    
Sum of 5 skinfolds (mm) e    Sum of 5 skinfolds (mm) g    
CT genotype 1.985 –2.715; 6.686 0.408 GT genotype 2.539 –2.134; 7.212 0.287 
CT genotype × time    GT genotype × time    
WC (cm) e    WC (cm) g    
CT genotype –0.888 –2.058; 0.283 0.137 GT genotype –0.756 –1.920; 0.408 0.203 
CT genotype × time    GT genotype × time    
HC (cm) e    HC (cm) g    
CT genotype –0.896 –2.015; 0.223 0.117 GT genotype –0.763 –1.876; 0.350 0.179 
CT genotype × time    GT genotype × time    
WHR (units) e    WHR (units) g    
CT genotype –0.0008 –0.0096; 0.0080 0.857 GT genotype –0.0007 –0.0094; 0.0081 0.883 
CT genotype × time    GT genotype × time    
WHtR (units) e    WHtR (units) g    
CT genotype –0.0013 –0.0076; 0.0049 0.683 GT genotype 0 –0.0062; 0.0062 0.995 
CT genotype × time    GT genotype × time    
Systolic BP (mmHg) e    Systolic BP (mmHg) g    
CT genotype –2.167 –3.965; –0.368 0.018 GT genotype –2.293 –4.081; –0.506 0.012 
CT genotype × time    GT genotype × time    
Diastolic BP (mmHg) e    Diastolic BP (mmHg) g    
CT genotype –1.078 –2.109; –0.047 0.040 GT genotype –1.092 –2.117; –0.068 0.037 
CT genotype × time    GT genotype × time    
Glucose (mmol/L) e    Glucose (mmol/L) g    
CT genotype –0.0003 –0.0643; 0.0638 0.993 GT genotype 0 –0.064; 0.064 0.996 
CT genotype × time    GT genotype × time    
Insulin (mU/L) e    Insulin (mU/L) g    
CT genotype –0.551 –1.270; 0.169 0.134 GT genotype –0.559 –1.274; 0.157 0.126 
CT genotype × time    GT genotype × time    
Cholesterol (mmol/L) e    Cholesterol (mmol/L) g    
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CT genotype 0.104 –0.015; 0.224 0.086 GT genotype 0.129 0.010; 0.247 0.033 
CT genotype × time    GT genotype × time    
HDL-cholesterol (mmol/L) e    HDL-cholesterol (mmol/L) g    
CT genotype 0.017 –0.036; 0.069 0.537 GT genotype 0.011 –0.041; 0.063 0.673 
CT genotype × time    GT genotype × time    
LDL-cholesterol (mmol/L) e    LDL-cholesterol (mmol/L) g    
CT genotype 0.086 –0.027; 0.199 0.136 GT genotype 0.102 –0.010; 0.215 0.075 
CT genotype × time    GT genotype × time    
Triglycerides (mmol/L) f    Triglycerides (mmol/L) h    
CT genotype –0.215 –0.458; 0.027 0.082 GT genotype –0.219 –0.461; 0.023 0.076 
CT genotype × time 0.013 0.001; 0.026 0.039 GT genotype × time 0.013 0.001; 0.026 0.038 
Energy intake (kcal) e1    Energy intake (kcal) g1    
CT genotype –91.503 –199.402; 16.395 0.096 GT genotype –104.993 –212.279; 2.293 0.055 
CT genotype × time    GT genotype × time    
Protein (g) e1    Protein (g) g1    
CT genotype –4.726 –8.999; –0.453 0.030 GT genotype –5.293 –9.544; –1.043 0.015 
CT genotype × time    GT genotype × time    
Lipids (g) e1    Lipids (g) g1    
CT genotype –3.249 –8.413; 1.915 0.218 GT genotype –4.131 –9.273; 1.010 0.115 
CT genotype × time    GT genotype × time    
Carbohydrates (g) e1    Carbohydrates (g) g1    
CT genotype –10.685 –23.972; 2.603 0.115 GT genotype –11.551 –24.767; 1.664 0.087 
CT genotype × time    GT genotype × time    
Protein E% f    Protein E% h    
CT genotype 1.491 –0.258; 3.240 0.095 GT genotype 1.460 –0.284; 3.203 0.101 
CT genotype × time –0.098 –0.192; –0.004 0.042 GT genotype × time –0.097 –0.191; –0.003 0.044 
Lipids E% e    Lipids E% g    
CT genotype 0.008 –0.849; 0.866 0.985 GT genotype –0.037 –0.891; 0.817 0.932 
CT genotype × time    GT genotype × time    
Carbohydrates E% e    Carbohydrates E% h    
CT genotype 0.278 –0.742; 1.298 0.593 GT genotype –0.418 –8.443; 0.089 0.055 
CT genotype × time    GT genotype × time 0.241 0.021; 0.461 0.032 
MPO/kg e    MPO/kg g    
CT genotype –0.056 –0.159; 0.047 0.283 GT genotype –0.064 –0.166; 0.039 0.222 
CT genotype × time    GT genotype × time    
Standard. PA score e    Standard. PA score g    
CT genotype 0 –0.122: 0.122 0.999 GT genotype –0.022 –0.143; 0.100 0.728 
CT genotype × time    GT genotype × time    
e Coefficient can be interpreted as the mean difference in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage 
from daily energy intake (E%) between NPY rs16139 CT and TT genotype at each timepoint. 
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f Difference in the rate of change in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage from daily energy intake 
(E%) between rs16139 CT and TT genotype can be calculated as the sum of main effect coefficient and time × interaction coefficient at given timepoint. 
g Coefficient can be interpreted as the mean difference in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage 
from daily energy intake (E%) between rs17149106 GT and GG genotype at each timepoint. 
h Difference in the rate of change in anthropometrical measurements, blood pressure, metabolic biomarkers, daily energy intake (kcal), nutrient intake (g) and nutrient intake as a percentage from daily energy intake 
(E%) between rs17149106 GT and GG genotype can be calculated as the sum of main effect coefficient and time × interaction coefficient at given timepoint.  
1 adjusted for body weight 





Table 3. The rate of change per year in anthropometric measurements, blood pressure and dietary 
intake (mean and 95% CI) of the ECPBHS sample according to the linear mixed-effects regression 
models with NPY rs5574 genotype × time interaction, rs16147 genotype × time interaction, rs16139 × 
time interaction and rs17149106 × interaction. 
rs5574 TT genotype CT genotype CC genotype 
WHR (units) 0.0033 (0.0025; 0.0041)c 0.0039 (0.0034; 0.0044) 0.0045 (0.0039; 0.0052)c 
Diastolic BP (mmHg) 0.310 (0.181; 0.439)c 0.448 (0.364; 0.531) 0.503 (0.395; 0.612)c 
Energy intake (kcal) –51.818 (65.375; –38.261)c –39.090 (–48.189; –29.991) –34.131 (–45.692; –22.570)c 
Carbohydrates (g) –10.505 (12.439; –8.571)c –8.426 (–9.729; –7.124) –7.969 (–9.617; –6.320)c 
rs16147 TT genotype CT genotype CC genotype 
Sum of 5 skinfolds (mm) 2.550 (2.135; 2.964)ac 2.044 (1.757; 2.331)a 1.935 (1.527; 2.343)c 
WC (cm) 1.197 (1.081; 1.312)a 1.045 (0.965; 1.125)a 1.035 (0.921; 1.148) 
WHR (units) 0.0048 (0.0041; 0.0055)ac 0.0038 (0.0034; 0.0043)a 0.0034 (0.0027; 0.0041)c 
WHtR (units) 0.0059 (0.0053; 0.0066)ac 0.0050 (0.0045; 0.0054)a 0.0050 (0.0043; 0.0056)c 
Diastolic BP (mmHg) 0.514 (0.394; 0.634)c 0.442 (0.359; 0.526) 0.345 (0.228; 0.463)c 
rs16139 TT genotype CT genotype  
Triglycerides (mmol/L) 0.018 (0.014; 0.023)d 0.031 (0.020; 0.043)d  
Protein E% 0.317 (0.284; 0.350)d 0.219 (0.131; 0.307)d  
rs17149106 GG genotype GT genotype  
Triglycerides (mmol/L) 0.018 (0.014; 0.023)d 0.031 (0.020; 0.043)d  
Protein E% 0.317 (0.284; 0.350)d 0.220 (0.132; 0.308)d  
Carbohydrates E% –0.584 (–0.662; –0.506)d –0.343 (–0.549; –0.137)d  
a p < 0.05 significant difference in the rate of change between rs5574 TT and CT genotypes or rs16147 TC and CC genotypes. 
c p < 0.05 significant difference in the rate of change between rs5574 TT and CC genotypes or rs16147 TT and CC genotypes. 
d p < 0.05 significant difference in the rate of change between rs16139 TT and CT genotypes or rs17149106 GG and GT genotypes. 
WC – waist circumference; WHR – waist-to-hip ratio; WHtR – waist-to-height ratio; BP – blood pressure 
 
